UCB UCB SA

EBR · BE · Healthcare · Biotechnology · ucb.com
203.40EUR+1.24%Mkt Cap: 41.63B $P/E: 17.75

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…

HeadlineSourceTime
Older
Zonebourse
Zonebourse
boursedirect.fr
IIdeal Investisseur
IIdeal Investisseur
zonebourse.com
Zonebourse Suisse
zonebourse.com
TradingView
Zonebourse Suisse
boursedirect.fr
AArtsenkrant
boursedirect.fr
UCB (UCBJY) Upgraded to Buy: Here's Why

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks
LLe Temps
LLa Liberté
Zonebourse Suisse
ch.zonebourse.com
FFrapp
Zonebourse
dhnet.be
La Libre.be
L'Echo
BBelga Share
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Zacks
L'Echo
Idéal Investisseur
LLe Soir
La Libre.be
Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.

Bloomberg
Zonebourse
Zonebourse Suisse
L'Echo
boursedirect.fr
Zonebourse
Boursorama
boursedirect.fr
L'Echo
boursedirect.fr
Zonebourse
boursedirect.fr
L'Echo
Yahoo Finance France
Investing.com France
UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ...

UCB SA (UCBJF) reports 23% net sales growth to EUR4.1 billion, with BIMZELX doubling to EUR1.5 billion and upgraded full-year guidance reflecting robust operating leverage.

GuruFocus.com
DDHnet
La Libre.be
La Libre.be
DDHnet